4月28日晚间,CXO龙头药明康德(603259.SH/2359.HK)的一季度业绩报告出炉,营收及三个口径下的利润均重回双位数增长,再次释放了强劲回暖信号。站在股东回报的视角,2025年一季度,药明康德稀释每股收益(EPS)达到1.28元,同比大幅增长93.9%,增速高于三个口径下的利润指标增速,显示股东收益有效提升。每股收益增速快于利润增速,主要得益于药明康德在过去一年持续实施的股份回购注销,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.